MK-1293 Insulin Glargine is a Safe and Effective Treatment Option for Type 2 Diabetes
Injection site reactions reported in 1.9% of participants in the MK-1293 group, including pain and discomfort.
Endocrinology Advisor interviewed experts to explore mechanisms, clinical implications, and research needs pertaining to the diabetes-dementia link.
SGLT-2i exhibited superior effects in terms of weight loss and did not increase the risk for hypoglycemia in dual therapy with sulfonylurea.
Investigators examined the effects of a 12-month collaborative care program for patients with late-life depression on the 9-year incidence of diabetes in older individuals.